Literature DB >> 15356641

Pretransplant imatinib can improve the outcome of nonmyeloablative stem cell transplantation without increasing the morbidity in Philadelphia chromosome-positive chronic myeloid leukemia.

D-W Kim, Y-J Chung, S Lee, Y-J Kim, N-G Chung, J A Kim, I-H Oh, T-G Kim, Y-L Kim, H-G Goh, S-H Kim, B Cho, H-J Kim, C-K Min, J W Lee, J Y Jin, C-W Han, J W Kim, W-S Min, H-K Kim, C-C Kim, H J Kim.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15356641     DOI: 10.1038/sj.leu.2403502

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  2 in total

1.  The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia.

Authors:  Vivian G Oehler; Ted Gooley; David S Snyder; Laura Johnston; Allen Lin; Carrie C Cummings; Su Chu; Ravi Bhatia; Stephen J Forman; Robert S Negrin; Frederick R Appelbaum; Jerald P Radich
Journal:  Blood       Date:  2006-10-24       Impact factor: 22.113

2.  Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).

Authors:  Martin Henkes; Heiko van der Kuip; Walter E Aulitzky
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.